- Report
- March 2024
- 186 Pages
Global
From €3237EUR$3,374USD£2,781GBP
€3596EUR$3,749USD£3,090GBP
- Report
- February 2024
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1919EUR$2,000USD£1,648GBP
- Report
- September 2021
- 40 Pages
China
From €2494EUR$2,600USD£2,143GBP
- Report
- January 2019
- 212 Pages
Global
From €21104EUR$22,000USD£18,130GBP
- Report
- March 2024
- 94 Pages
Global
From €3500EUR$3,908USD£3,112GBP
Ibandronate is a medication used to treat osteoporosis and other bone diseases. It belongs to a class of drugs known as bisphosphonates, which are used to reduce the risk of fractures in people with weakened bones. Ibandronate works by slowing down the breakdown of bone and increasing bone density. It is also used to treat Paget's disease of bone, a condition in which the bones become weak and deformed.
Ibandronate is available in both oral and intravenous forms. The oral form is taken once a month, while the intravenous form is given every three months. Common side effects of ibandronate include nausea, vomiting, constipation, and abdominal pain.
Ibandronate is a key player in the Endocrine and Metabolic Disorders Drugs market. It is used to treat a variety of bone diseases, including osteoporosis, and is an important part of the treatment regimen for these conditions.
Some companies in the Ibandronate market include Amgen, Novartis, and Teva Pharmaceuticals. Show Less Read more